Together is a new resource for anyone affected by pediatric cancer - patients and their parents, family members, and friends.
Together Logo
About Pediatric Cancer
Life After Cancer
Teens&20s
Together Blog
The Together Blog is a resource that delivers timely topics on childhood cancer from providers, families, patients.
Together Community
The Together Community is a place where anyone affected by pediatric cancer can connect and support one another.
Acute Lymphoblastic Leukemia (ALL)
Acute Myeloid Leukemia (AML)
See more types of leukemia
Brain and Spinal Cord Tumors
See more brain and spinal tumors
More Cancer Types
See more types of pediatric cancer
Pediatric Cancer Care Team
Inherited Risk and Genetic Testing
Understanding Cancer
Role of Cancer Research
Learn More About Pediatric Cancer
Childhood Cancer Diagnosis
Reading a Pathology Report
Questions to Ask after Diagnosis
CT (Computed Tomography) Scan
MRI (Magnetic Resonance Imaging)
PET Scans (Positron Emission Tomography)
VCUG (Voiding Cystourethrogram)
See more imaging tests
Bone Marrow / Hematopoietic Cell Transplant
See more treatment options
Bone Marrow Aspiration and Biopsy
Find more procedures
ANC and Neutropenia
Loss of Appetite and Weight Loss
See more side effects of cancer treatment
List of Medicines
Learn more about clinical trials
Explore More Diagnosis and Treatment
See more rehabilitation services
Caring for an Ocular (Eye) Prosthesis
Care at Home After Eye Removal Surgery
Learn more about eye care
Immunity, Illness, and Infection
Preventing Infection
Learn more about the immune system
Psychology and Mental Health Services
Learn more about psychology and mental health services
Relapse - When Childhood Cancer Comes Back
Enteral Nutrition (Tube Feeding)
Nutrition and Side Effects
See more about clinical nutrition
Communicating with the Palliative Care Team
Planning for End of Life Care
Learn more about palliative care
Learn More About Care and Support
Navigating Health Care
Waiting for Test Results
Paying for Cancer Care
Learn how to navigate the healthcare experience
Classroom Accommodations
Learn more about school support
Support Networks for Parents
Supporting Marriages
Parenting Siblings
Find more support for parents
Building Better Communication
Offering Help to Families
Riley Takes Medicine Coloring Book [PDF]
Early Childhood Milestones
Questions to Ask Your Care Team
How to Talk to Your Child about Cancer
Spirituality and Faith
After the Death of a Child
Find More Support for Families
Be Your Own Health Care Advocate
Katie's Story: Building Relationships with Health Care Providers
Learn more about being your own health care advocate
School and Work
Financial Aid and College Scholarships
Workplace Training and Services
Find more school and work resources
Long-Term and Late Effects
Cognitive Late Effects
Cardiac (Heart) Late Effects
Bladder Late Effects
Breast Cancer Risk
Find more late effects
Physical Activity After Cancer
Healthy Eating After Cancer
Learn more about healthy living
Post-Treatment and Beyond
Transition Off Treatment
How to Make the Transition from Pediatric to Adult Health Care
Learn more about post treatment
If I Had Cancer, Will My Children Get Cancer?
Emotional Well-Being
Childhood Cancer Survivor Stories: Meet the Patients
Learn More About Life After Cancer
Cytokine Release Syndrome (CRS) After Immunotherapy
Cytokine Release Syndrome Current Page
What Is Cytokine Release Syndrome?
Cytokine release syndrome (CRS) is a collection of symptoms that can develop as a side effect of certain types of immunotherapy, especially those which involve T-cells. The syndrome occurs when immune cells are activated and release large amounts of cytokines into the body. Cytokines are small proteins that act as cell messengers to help direct the body's immune response. However, high levels of cytokines may cause increased inflammation throughout the body. This can be harmful and interfere with a number of body functions. In severe cases, CRS can cause organ failure and even death.
CRS usually develops within 3-14 days after T cell based immunotherapy. It often begins with fever and flu-like symptoms but can worsen quickly and cause serious illness.
Management of CRS includes monitoring and supportive care to control symptoms. Some patients may need intensive care and medicines to lower the immune response (immunosuppressive drugs).
At-risk patients will be monitored for about a month after an immunotherapy infusion. Patients who develop symptoms usually improve within 1-2 weeks. Most patients do not have long-term problems from cytokine release syndrome.
Cytokine Release Syndrome Symptoms
Symptoms of CRS are caused by a widespread immune response in the body. Different organ systems can be affected with a range of symptoms. In some cases, CRS can cause life-threatening changes in heart, lung, kidney, liver, and brain function.
Many CRS symptoms can have other causes. Neurotoxicity and other side effects of immune therapies can happen with or without CRS symptoms. The care team will perform tests and monitor symptoms to plan the best course of treatment.
Body System Affected
Possible Symptoms
General Fever, chills, fatigue, weakness, loss of appetite, nausea, vomiting, diarrhea, headache, joint or muscle aches, skin rash
Heart and blood vessels Low blood pressure, increased heart rate, irregular heartbeat, decreased heart function, swelling and buildup of fluids (edema)
Brain and nervous system Headache, confusion, dizziness, seizures, hallucinations, decreased coordination, problems talking or swallowing, shaking, problems controlling movements
Lungs Cough, shortness of breath, decreased lung function, reduced oxygen levels
Other changes and laboratory markers Decreased kidney or liver function, increased cytokine levels in the blood, change in electrolytes, change in blood clotting
Causes of Cytokine Release Syndrome
Cytokine release syndrome occurs after treatment with immunotherapy that activates T cells to fight cancer. These therapies trigger a widespread immune inflammatory response due to the release of cytokines.
In childhood cancer, immunotherapies most often associated with CRS include blinatumomab and tisagnlecleucel.
Blinatumomab (Blincyto®) is a bispecific T-cell engager (BITE) monoclonal antibody. This medicine works by causing T cells to target a protein called CD19 found on some types of leukemia cells.
Tisagenlecleucel (Kymriah®) is a CAR T-cell immunotherapy. It works by engineering T cells to have special receptors called chimeric antigen receptors (CARs). These receptors help T cells recognize and attack cancer cells.
Currently, CAR T-cell immunotherapy in pediatric cancer is most often used in children with relapsed or refractory acute lymphoblastic leukemia (ALL).
Chimeric antigen receptor, or CAR T-cell therapy, is one treatment associated with cytokine release syndrome. CAR T-cell therapy doctors return modified T cells to patients to recognize and attack cancer cells.
Cytokine Release Syndrome Treatment
Management of CRS includes monitoring and laboratory tests, treating specific symptoms, and medicines to lower the immune response. The care team will watch for worsening of symptoms and signs of organ failure. Treatments are based on the severity or grade of cytokine release syndrome. Children with more extensive disease related to their cancer are at higher risk for more severe CRS.
Laboratory Tests and Symptom Monitoring
Patients at risk for CRS should be monitored closely, especially during the first weeks after immunotherapy.
Monitoring for CRS includes:
Breathing rate
Oxygen levels
Neurological exam to watch for changes in brain and nervous system function
Laboratory tests such as blood counts, electrolytes, indicators of kidney and liver function, cytokines and other markers of immune function, and work-up for infection
Supportive Care and Symptom Management
Medical care for CRS centers on managing the patient's specific symptoms. Some patients may need care in an ICU setting.
Supportive care may include:
IV fluids
Oxygen or ventilator support
Medicines to regulate blood pressure
Medicines to support heart function
Blood product transfusions
Medicines or dialysis to support kidney function
Prevention of Seizures
Patients at risk for brain and nervous system effects may be given a medication such as levetiracetam (Keppra®) to help prevent seizures that can occur with immunotherapy.
Medicines to Decrease the Immune Response
Patients with severe CRS are treated with drugs that counteract the immune response. These medicines include targeted therapies to block specific cytokines, as well as more general immunosuppressive drugs.
A common cytokine target is interleukin-6 (IL-6). The drugs most often used to interfere with IL-6 are tocilizumab and siltuximab.
Corticosteroids such as methylprednisolone or dexamethasone may also be used to help reduce inflammatory and immune responses; they do not target specific cytokines but rather provide broader immunosuppression.
Because immunosuppressive drugs have the potential to interfere with the anti-cancer effect of immunotherapy and also have other side effects, these medicines are not used in all cases.
The care team will weigh potential benefits and risks in deciding the best plan of treatment.
Cytokine release syndrome is a serious complication that can occur with immunotherapy. At-risk patients are monitored closely. Treatments focus on managing symptoms and supporting organ function.
Your doctor can help you understand cytokine release syndrome and know whether your child is at risk. Always talk to your care team about any health concerns, and report changes in symptoms that occur during or after treatment.
Together does not endorse any branded product mentioned in this article.
Reviewed: March 2019
Immunotherapy is a cancer treatment that uses the immune system to fight cancer. This therapy works by helping the immune system find cancer cells and attack them or increase the immune response to cancer.
Learn about different types of immunotherapy.
The immune system is the body's defense against infection. A network of special cells, tissues, and organs work together to protect the body from a variety of "invaders" or germs.
Acute lymphoblastic leukemia (ALL) is the most common type of childhood cancer, a cancer of the blood and bone marrow.
Learn about ALL diagnosis and treatment
This information is general education and does not replace medical advice. Call your physician or care team for medical advice. If you print or download this or any content, you should check back after 72 hours to make sure it has not changed.
Together powered by St. Jude Children's Research Hospital
Locate A Clinical Trial
Subscribe and receive occasional updates about new content and features.
© 2023 St. Jude Children's Research Hospital. All rights reserved.